Пређи на садржај

Naltrekson

С Википедије, слободне енциклопедије
Naltrekson
Klinički podaci
Prodajno imeCelupan, MorViva, N-Cyclopropylmethylnoroxymorphone, Naltrexona [INN-Spanish]
Drugs.comMonografija
Način primeneOralno
Farmakokinetički podaci
Poluvreme eliminacije4 h
IzlučivanjeRenalno
Identifikatori
CAS broj16590-41-3 ДаY
ATC kodN07BB04 (WHO)
PubChemCID 5360515
DrugBankDB00704 ДаY
ChemSpider4514524 ДаY
KEGGC07253 ДаY
ChEBICHEBI:7465 ДаY
ChEMBLCHEMBL142 ДаY
Hemijski podaci
FormulaC20H23NO4
Molarna masa341,401
  • [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O
  • InChI=1S/C20H23NO4/c22-13-4-3-12-9-15-20(24)6-5-14(23)18-19(20,16(12)17(13)25-18)7-8-21(15)10-11-1-2-11/h3-4,11,15,18,22,24H,1-2,5-10H2/t15-,18+,19+,20-/m1/s1 ДаY
  • Key:DQCKKXVULJGBQN-XFWGSAIBSA-N ДаY
Fizički podaci
Tačka topljenja168—170 °C (334—338 °F)

Naltrekson je organsko jedinjenje, koje sadrži 20 atoma ugljenika i ima molekulsku masu od 341,401 Da.[1][2][3][4][5]

Osobina Vrednost
Broj akceptora vodonika 5
Broj donora vodonika 2
Broj rotacionih veza 2
Particioni koeficijent[6] (ALogP) 1,7
Rastvorljivost[7] (logS, log(mol/L)) -2,0
Polarna površina[8] (PSA, Å2) 70,0
  1. ^ Schmitz JM, Stotts AL, Rhoades HM, Grabowski J: Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001 Mar-Apr;26(2):167-80. PMID 11316375
  2. ^ Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R: Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, Naltrexone in the treatment of alcoholism. Alcohol Clin Exp Res. 2008 Jan;32(1):85-91. Epub 2007 Dec 7. PMID 18070245
  3. ^ Ray LA, Chin PF, Miotto K: Naltrexone for the treatment of alcoholism: clinical findings, mechanisms of action, and pharmacogenetics. CNS Neurol Disord Drug Targets. 2010 Mar;9(1):13-22. PMID 20201811
  4. ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126.  уреди
  5. ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958.  уреди
  6. ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o. 
  7. ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.  уреди
  8. ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.  уреди

Spoljašnje veze

[уреди | уреди извор]


Molimo Vas, obratite pažnju na važno upozorenje
u vezi sa temama iz oblasti medicine (zdravlja).